---
title: "Pharmaron Beijing 2025 net profit down 7.2% Y/Y"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281016506.md"
description: "Pharmaron Beijing 2025 net profit down 7.2% Y/Y"
datetime: "2026-03-30T12:08:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281016506.md)
  - [en](https://longbridge.com/en/news/281016506.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281016506.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/281016506.md) | [繁體中文](https://longbridge.com/zh-HK/news/281016506.md)


# Pharmaron Beijing 2025 net profit down 7.2% Y/Y



### Related Stocks

- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md)
- [Pharmaron (300759.CN)](https://longbridge.com/en/quote/300759.CN.md)

## Related News & Research

- [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/en/news/281662341.md)
- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/en/news/281458440.md)
- [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/en/news/281501537.md)
- [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/en/news/281343251.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md)